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The Src homology 2 domain-containing protein tyro-
sine phosphatases SHP-1 and SHP-2 play an important
role in many intracellular signaling pathways. Both
SHP-1 and SHP-2 have been shown to interact with a
diverse range of cytosolic and membrane-bound signaling
proteins. Generally, SHP-1 and SHP-2 perform opposing
roles in signaling processes; SHP-1 acts as a negative reg-
ulator of transduction in hemopoietic cells, whereas
SHP-2 acts as a positive regulator. Intriguingly, SHP-1 has
been proposed to play a positive regulating role in non-
hemopoietic cells, although the mechanisms for this are
not understood. Here we show that green fluorescent pro-
tein-tagged SHP-1 is unexpectedly localized within the
nucleus of transfected HEK293 cells. In contrast,
the highly related SHP-2 protein is more abundant within
the cytoplasm of transfected cells. In accordance with
this, endogenous SHP-1 is localized within the nucleus of
several other nonhemopoietic cell types, whereas SHP-2
is distributed throughout the cytoplasm. In contrast,
SHP-1 is confined to the cytoplasm of hemopoietic cells,
with very little nuclear SHP-1 evident. Using chimeric
SHP proteins and mutagenesis studies, the nuclear local-
ization signal of SHP-1 was identified within the C-
terminal domain of SHP-1 and found to consist of a short
cluster of basic amino acids (KRK). Although the KRK
motif resembles half of a bipartite nuclear localization
signal, it appears to function independently and is abso-
lutely required for nuclear import. Our findings show
that SHP-1 and SHP-2 are distinctly localized within non-
hemopoietic cells, with the localization of SHP-1 differing
dramatically between nonhemopoietic and hemopoietic
cell lineages. This implies that SHP-1 nuclear import is a
tightly regulated process and indicates that SHP-1 may
possess novel nuclear targets.
Tyrosine phosphorylation plays a central role in the transduc-
tion of signals from the cell surface to the nucleus. Protein-
tyrosine phosphatases (PTPs)1 act both as positive and negative
regulators of signal transduction (1). Numerous PTPs have
been identified so far, including the extensively studied SHP-1
(previously known as PTP1C, SHPTP-1, SHP, and HCP) and
SHP-2 (previously termed SHPTP-2, Syp, PTP2C, and PTP1D)
intracellular proteins (1–3). SHP-1 is expressed at high levels
in hemopoietic cells and moderately in many other cell types,
especially malignant epithelial cells (4–6), whereas SHP-2 is
more widely distributed. Both proteins are structurally very
similar, comprising two tandem Src homology 2 domains at the
N terminus, a single central catalytic domain, and a C-terminal
domain (7, 8). The Src homology 2 domains recruit SHP-1 and
SHP-2 to tyrosine-phosphorylated molecules, enabling dephos-
phorylation to be performed by the catalytic domain (9). Consid-
ering the conserved nature of SHP-1 and SHP-2, it is perplexing
that when integrated into signaling pathways, both proteins
perform opposing roles. Generally, SHP-1 acts as a negative
regulator of signal transduction, terminating signals from a
diverse range of signaling molecules, including the epidermal
growth factor receptor (10), interleukin 3 receptor (11), c-kit
(12), colony-stimulating factor 1 receptor (13), B- and T-cell
antigen receptors (14, 15), and the receptor-associated Janus-
activated kinases (16–18). In contrast, SHP-2 plays a positive
role in many signaling systems and can act as an adapter
protein, linking tyrosine kinases and Grb2 to activate the mi-
togen-activated protein kinase pathway (19, 20).
Recent studies show that the role of SHP-1 depends on the
cell type (21, 22). SHP-1 has a positive effect on mitogenic
signaling in several nonhemopoietic cell types, which concurs
with its overexpression in certain tumor cells. Overexpression
of a catalytically inactive mutant of SHP-1 in HEK293 cells
strongly suppresses mitogen-activated pathways and results in
decreased cell growth, DNA synthesis, and the transcription of
early response genes (21). Furthermore, transfection of HeLa
cells with inactive SHP-1 reduces the signal transducer and
activator of transcription (STAT)-DNA binding induced by
interferon g and epidermal growth factor (22). As yet, the
molecular basis for the apparent opposite effects of SHP-1 in
different cell systems has yet to be defined, although the
phosphatase domain appears to be critical.
It is widely assumed that SHP-1 and SHP-2 are cytoplasmic
proteins and have similar intracellular distributions. In this
paper we demonstrate a novel nuclear localization for SHP-1 in
nonhemopoietic cells, whereas SHP-2 is distributed throughout
the cytoplasm. We also show that the nuclear import of SHP-1
is dependent on a short region of basic amino acid residues in
the C-terminal domain that resembles half of a bipartite nu-
clear localization sequence. In addition, we show that SHP-1
localization differs between nonhemopoietic and hemopoietic
cells, with the SHP-1 protein being present almost entirely
within the cytoplasm of hemopoietic cell lines. These results
have implications regarding the function of SHP-1 in nonhe-
mopoietic cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—All cell lines were obtained from the
American Type Culture Collection and maintained at 37 °C in a humid-
ified 5% CO2 incubator. HEK293, HeLa, and A549 cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
vine serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 mg of
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streptomycin (Life Technologies, Inc.). MCF-7 cells were maintained in
the same growth medium supplemented with 10 mg/ml bovine insulin
(Sigma). HL-60, U-937, and Jurkat cells were grown in RPMI 1640
medium (Life Technologies) supplemented with 10% fetal bovine se-
rum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 mg of strepto-
mycin. The day before transfection, 5 3 104 HEK293 cells were seeded
per well of a 24-well plate. The medium was exchanged for complete
medium lacking antibiotics, and the cells were transfected with 1 mg of
plasmid DNA and 1 ml of LipofectAMINE 2000 in OptiMEM (Life
Technologies) for 6 h according to the manufacturer’s instructions. After
a change to complete medium, the cells were grown for a further 24 h
before processing for microscopy.
Construction of green fluorescent protein-tagged SHP-1 and SHP-2—
Green fluorescent protein (GFP)-tagged SHP-1 and SHP-2 fusion con-
structs were generated using the strategy of overlapping recombination
polymerase chain reaction (23). Platinum Pfx polymerase (Life Tech-
nologies) was used for all polymerase chain reactions. The SHP-1 coding
sequence was amplified using a forward SHP-1 primer containing an
XhoI site and a Kozak sequence (59-ccctcgagcccacatggtgaggtggtttcaccg-
39) and a downstream joining primer (59-cctcgcccttgctcaccatcttcctctt-
gagggaaccc-39). GFP (enhanced GFP; CLONTECH) was amplified
using a forward joining primer (59-gggttccctcaagaggaagatggtgag-
caagggcgagg-39) and a reverse GFP primer containing an XhoI site
(59-ccctcgagttacttgtacagctcgtccat-39). The two resulting products were
mixed, and a secondary polymerase chain reaction was performed
using the forward SHP-1 and reverse GFP primers. The product was
ligated as an XhoI fragment into the expression vector MSCVpuro
(CLONTECH). GFP-tagged SHP-2 was constructed in a similar manner
using a forward SHP-2 primer (59-ccctcgagccaccatgacatcgcggagatggtt-
39), joining primers (59-cctcgcccttgctcaccattctgaaacttttctgctgttg-39 and
59-caacagcagaaaagtttcagaatggtgagcaaggagggcgagg-39), and a reverse
GFP primer.
Construction of SHP-1/SHP-2 Chimeras—The method of overlap-
ping recombination polymerase chain reaction was used to generate
cDNAs encoding chimeric SHP-1/SHP-2 proteins from GFP-tagged
SHP-1 and SHP-2 templates. SHP-2/1A, SHP-2/1B, and SHP-2/1C were
constructed using the forward SHP-2 primer and reverse GFP primer
with joining primers (SHP-2/1A, 59-gtgcagatcctacctctgaaaggtggtaccatg-
gccacatgtctg-39 and 59-catacatgtggccatggtaccacctttcagaggtaggatctgcac-
39; SHP-2/1B, 59-caaacttctctacagccgaaaagaggggcagcggccagagaacaag-39
and 59-cttgttctctggccgctgcccctcttttcggctgtagagaagtttg-39; and SHP-2/1C,
59-ctatatggcggtccagcattatattgaaacaactaagaagaagctggaggtcctgcag-39
and 59-ctgcaggacctccagcttcttcttagttgtttcaatataatgctggaccgccatatag-39).
SHP-1/2 was constructed using the forward SHP-2 primer and reverse
GFP primer with joining primers 59-catcgcccagttcattgaaaccctacagcgca-
ggattgaagaag-39 and cttcttcaatcctgcgctgtagggtttcaatgaactgggcgatg-39.
Each chimeric cDNA was cloned as an XhoI fragment into MSCVpuro.
Site-directed Mutagenesis of SHP-1 Basic Domains—The basic resi-
dues in the C-terminal domain of GFP-tagged SHP-1 were mutated to
alanines using the QuikChange site-directed mutagenesis kit (Strata-
gene). Oligonucleotides used were BD1 (59-cagttcattgaaaccactgcggcggc-
gctggaggtcctgcagtcg-39 and 59-cgactgcaggacctccagcgccgccgcagtggtttcaa-
tgaactg-39), BD2 (59-gaacaagagggaggaggcagtggcggcgcagcggtcagcagaca-
ag-39 and 59-cttgtctgctgaccgctgcgccgccactgcctcctccctcttgttc-39), and BD3,
(59gagcaagggttccctcgcggcggcgatggtgagcaagggcg-39 and 59cgcccttgctcacc-
atcgccgccgcgagggaacccttgctc-39), where underlined nucleotides indicate
mismatches.
Immunocytochemistry and Fluorescence Microscopy—HeLa, A549,
and MCF-7 cells were plated onto acid-washed glass coverslips at 50%
confluence and incubated overnight. HL-60, U-937, and Jurkat cells
were spun onto glass slides at 500 rpm for 5 min using a Cytospin 3
(Shandon). Cells were washed for 5 min in phosphate-buffered saline
(PBS) and then fixed in 4% paraformaldehyde in PBS for 20 min. After
a further 5-min wash in PBS, cells were incubated in PBS, 10% normal
goat serum (NGS), and 0.2% Triton X-100 for 30 min. The cells were
then incubated overnight at 4 °C with either anti-SHP1 or anti-SHP2
mouse monoclonal antibodies (Transduction Laboratories) diluted
1:500 (0.5 mg/ml) in PBS and 1% NGS. Cells were washed four times for
5 min in PBS, 10% NGS, and 0.2% Triton X-100 before Alexa 488-
conjugated goat anti-mouse antibody (Molecular Probes) was applied at
a 1:200 dilution in PBS and 1% NGS for 1 h. After four additional 5-min
washes in PBS, 10% NGS, and 0.2% Triton X-100, the cells were
immersed briefly in distilled water and mounted in S3023 fluorescent
mounting medium (Dako). Transfected HEK293 cells were trypsinized
from the tissue culture plate and plated onto eight-well multichamber
slides (Lab-Tek, Nunc) at a density of 1000 cells per well. After 24 h, the
cells were washed in PBS and fixed in 4% paraformaldehyde in PBS for
20 min. After a brief wash in PBS, the cells were mounted in fluorescent
mounting medium and coverslipped. Alexa-488 and GFP fluorescence
was viewed at 467 nM using an Axiovert 135 microscope (Zeiss) coupled
to a monochrome light source (Photonics Polychrome II). A series of
optical scans through the z axis of the cells were captured using a
Hamamatsu digital camera, and image deconvolution was performed
with Openlab software (Improvision). The digitized images were pro-
cessed using Openlab software on a Power Macintosh G3.
RESULTS
SHP-1 Is Localized within the Nucleus of HEK293 Cells—A
knowledge of the intracellular distribution of nontransmem-
branal PTPs might give an insight into their cellular function
and regulation. Surprisingly, there is a paucity of data on the
intracellular localization of SHP-1 and SHP-2. It is widely
believed that both SHP-1 and SHP-2 are located within the
cytoplasm, presumably because their interactions with tyro-
sine-phosphorylated, membrane-associated proteins are well
documented. The localization of both SHP-1 and SHP-2 was
investigated by transiently transfecting HEK293 cells with
cDNAs encoding each wild-type SHP protein fused with a C-
terminal GFP tag. Unexpectedly, SHP-1 was found to be local-
ized predominantly within the nucleus of all transfected
HEK293 cells (Fig. 1A). In contrast, SHP-2 was distributed
throughout the cytoplasm of all transfected cells (Fig. 1B), with
little nuclear fluorescence evident. GFP protein alone was dis-
FIG. 1. Intracellular distributions
of SHP-1 and SHP-2 in transfected
HEK 293 cells. The fluorescence localiza-
tion of GFP-tagged SHP-1 (A), GFP-tagged
SHP-2 (B), and GFP (C) was compared in
transiently transfected HEK293 cells.
GFP-tagged proteins were expressed for
48 h, and their distribution was examined
by fluorescence microscopy. GFP-tagged
SHP-1 is present primarily in the nucleus
of transfected cells, whereas GFP-tagged
SHP-2 is distributed mainly within the
cytoplasm. GFP alone diffuses through-
out the cell. EGFP, enhanced GFP.
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tributed evenly throughout the cell (Fig. 1C). This nuclear
versus cytoplasmic distribution of overexpressed GFP-tagged
SHP-1 and SHP-2 appears to be consistent for a variety of
nonhemopoietic cells that have been tested (HeLa, MCF7,
A549, primary rat embryo fibroblast, and Chinese hamster
ovary cells; data not shown).
Endogenous SHP-1 Exhibits Contrasting Localization in
Nonhemopoietic and Hemopoietic Cell Lines—To exclude the
possibility that the observed nuclear localization of SHP-1 was
artifactual because of overexpression, the addition of GFP se-
quence, or both, the localization of endogenous SHP-1 was
studied in several nonhemopoietic cell lines. Although SHP-1 is
expressed predominantly in hemopoietic lineages, lower levels
of expression have been observed in HeLa cervical adenocarci-
noma, A549 lung carcinoma, and MCF-7 mammary adenocar-
cinoma cell lines (4, 6). Immunostaining using an SHP-1-spe-
cific antibody revealed that endogenous SHP-1 is localized
within the nucleus of these three cell types (Fig. 2, A–C). This
observation demonstrated that neither the overexpression of
SHP-1 nor addition of GFP to the C-terminal end of SHP-1 was
causing an alteration to its localization. Furthermore, detection
of SHP-2 in HeLa cells using an SHP-2-specific antibody con-
firmed that SHP-2 is localized throughout the cytoplasm (Fig.
2D). These results show that each SHP protein has a distinct
cellular distribution, with endogenous SHP-1 being localized
within the nuclear compartment of native cells.
FIG. 2. Localization of endogenous
SHP proteins in nonhemopoietic cell
lines. Cells were immunostained using
SHP-1- and SHP-2-specific monoclonal
antibodies. In accordance with experi-
ments performed using GFP-tagged pro-
teins, SHP-1 is present predominantly
within the nucleus of HeLa (A), MCF7 (B),
and A549 (C) cells. Likewise, SHP-2 is
present chiefly in the cytoplasm of cells
with a lesser degree of nuclear staining
(D). Shown is the change in relative fluo-
rescence intensity across the white lines,
with the black bars indicating the corre-
sponding nuclear region.
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Next, we wished to address whether SHP-1 localization dif-
fers between nonhemopoietic and hemopoietic cells. Previously,
SHP-1 has been found to be present in the cytoplasm of HL-60
promyeloblast cells (24) and primary human neutrophils (25).
Detection of SHP-1 in HL-60, U-937 macrophage, and Jurkat
T-cell leukemia cell lines by immunostaining revealed that
endogenous SHP-1 is present within the cytoplasm and ex-
cluded from the nucleus (Fig. 3). Therefore, SHP-1 localization
differs dramatically between the nonhemopoietic and hemopoi-
etic cell lines tested.
The C-terminal Domain of SHP-1 Is Responsible for Nuclear
Import—The maximum size of proteins allowed to passively
translocate through the nuclear pore complex is ;40–50 kDa;
larger proteins require an import signal (the nuclear localiza-
tion signal (NLS)) to be targeted to the nucleus (26). Because
the SHP-1-GFP fusion protein is ;93 kDa, active NLS-directed
transport across the nuclear membrane must occur. SHP-1 and
SHP-2 are closely related proteins and structurally very simi-
lar. They have nearly 55% overall sequence identity at the
amino acid level, with the tandem Src homology 2 domains and
catalytic domain exhibiting the highest level of similarity (Fig.
4A). To determine the region of SHP-1 responsible for nuclear
import, chimeric cDNAs were constructed (Fig. 4B), each fused
with a C-terminal GFP tag. When transiently expressed in
HEK293 cells, the three chimeric cDNAs encoding varying
lengths of SHP-2 with the C-terminal end of SHP-1 (SHP-2/
1-A, SHP-2/1-B, and SHP-2/1-C) were found to be localized
predominantly within the nuclei of transfected cells (Fig. 5,
A–C) and indistinguishable from wild-type SHP-1. This re-
vealed that the C-terminal domain of SHP-1 could replace the
analogous region of SHP-2 and could allow the otherwise
cytoplasmic SHP-2 molecule to efficiently enter the nucleus.
Therefore, it was likely that the C-terminal domain of SHP-1
harbored the signal sequence responsible for nuclear trans-
location. This was demonstrated by expressing a cDNA en-
coding SHP-1 with the C-terminal domain replaced by the
equivalent region of SHP-2 (SHP-1/2; Fig. 4B). The resulting
protein was unable to enter the nucleus and accumulated
within the cytosol of all transfected cells (Fig. 5D). Thus, the
C-terminal domain of SHP-1 is necessary for the nuclear
import of SHP-1. Furthermore, the C-terminal domain (ami-
no acids 519–595) linked to GFP (SHP-1C) entered the nu-
cleus of transfected HEK293 cells with high efficiency (Fig.
5E), indicating that the C-terminal domain was sufficient for
nuclear import.
A Short Basic Region within the C-terminal Domain Is Re-
sponsible for SHP-1 Nuclear Import—Basic domains are well
known to function as NLSs. Analysis of the C-terminal domains
of SHP-1 and SHP-2 revealed that several basic regions (BD1,
BD2, and BD3) are present within SHP-1 but not in SHP-2
(Fig. 6A). BD1 (TKKKL) is similar to the NLS of the SV40 T
antigen (Fig. 6B). BD2 (KVKK) and BD3 (KRK) together re-
FIG. 3. Localization of endogenous
SHP-1 in hemopoietic cell lines. The
distribution of SHP-1 in three hemopoi-
etic cell lines was determined by immu-
nostaining using an antibody specific to
the SHP-1 protein. SHP-1 is present al-
most entirely within the cytoplasm of
U937 (A), HL-60 (B), and Jurkat (C) cells.
Shown is the change in relative fluores-
cence intensity across the white lines,
with the black bars indicating the corre-
sponding nuclear region.
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semble the bipartite NLS of nucleoplasmin, consisting of two
short stretches of basic amino acids separated by 10–22 resi-
dues (Fig. 6C). To establish whether these putative NLS do-
mains were responsible for the nuclear import of SHP-1, each
domain was removed by mutating the basic residues to ala-
nines. Mutation of BD1 (SHP-1 K520A/K521A/K522A) resulted
in a protein that still efficiently entered the nucleus (Fig. 7A).
Likewise, mutation of BD2 (SHP-1 K576A/K578A/K579A) re-
FIG. 4. Structure of SHP-1, SHP-2,
and chimeric proteins. A, SHP-1 and
SHP-2 structure, showing the conserved
tandem Src homology 2 (SH2) domains,
the single catalytic domain, and the
degree of homology between them. B,
structure of the SHP-1/SHP-2 chimeric
molecules used to identify the C-terminal
domain as the mediator of SHP-1 nuclear
import.
FIG. 5. The C-terminal domain of
SHP-1 confers nuclear import. The
fluorescence localization of GFP-tagged
chimeras of SHP-1 and SHP-2 is shown.
HEK293 cells were transiently trans-
fected with cDNAs encoding chimeric pro-
teins comprising varying lengths of
SHP-1 and SHP-2 (see Fig. 4 and “Exper-
imental Procedures”). Chimeric proteins
containing regions of SHP-2 with the C-
terminal domain of SHP-1 were imported
into the nucleus (A–C). A protein consist-
ing of SHP-1 with the C-terminal domain
replaced by that of SHP-2 was unable to
enter the nucleus and accumulated in the
cytoplasm (D). The C-terminal domain of
SHP-1 alone was also able to direct GFP
into the nucleus with high efficiency (E).
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sulted in an SHP-1 protein that also entered the nucleus of
transfected cells (Fig. 7B). In contrast, mutation of BD3 (SHP-1
K593A/R594A/K595A) almost completely prevented nuclear
import, with the mutated SHP-1 protein accumulating within
the cytosol (Fig. 7C). This distribution resembled that of the
SHP-1/2 chimeric protein and indicated that the short KRK
sequence constituting BD3 was responsible for nuclear import.
Previously, it has been shown that mutations in either the
basic cluster of the bipartite NLS of nucleoplasmin have only a
partial effect on nuclear transport, with mutations in both
clusters required to abolish nuclear transport. On the basis of
these criteria, the BD2 and BD3 domains of SHP-1 do not form
a bipartite NLS, even though the amino acid sequence resem-
bles bipartite NLS from several nuclear proteins. Mutation of
BD3 completely prevents the nuclear import of SHP-1 (Fig.
7C), whereas a protein lacking both BD2 and BD3 shows a
similar distribution (Fig. 7D). Therefore, unusually, the short
KRK motif present at the extreme C-terminal end of SHP-1 is
absolutely required and appears solely responsible for nuclear
import.
DISCUSSION
We have shown using GFP fusion proteins that SHP-1 is
present predominantly within the nuclear compartment of
HEK293 cells, an observation that extends to a variety
of transfected nonhemopoietic cells. In contrast, a GFP fusion
of the closely related protein SHP-2 is localized throughout the
cytoplasm. Immunostaining of SHP-1 in several nonhemopoi-
etic cell types reinforced the experiments performed with GFP-
tagged proteins, demonstrating that the distribution of SHP-1
was not influenced by overexpression or the addition of a GFP
tag. Endogenous SHP-1 clearly localized to the nucleus of three
nonhemopoietic cell lines that are known to express readily
detectable amounts of SHP-1. In contrast, endogenous SHP-2
was distributed throughout the cytoplasm in these cell types.
Furthermore, the localization of SHP-1 differs dramatically
between nonhemopoietic and hemopoietic cells. The HL-60,
U-937, and Jurkat cells tested each exhibited SHP-1 staining
that was confined within the cytoplasm. Therefore, we have
revealed a novel nuclear import of the SHP-1 protein that
appears to be restricted to nonhemopoietic cells.
The use of chimeric proteins showed that the C-terminal
domain of SHP-1 harbors the signal required for the nuclear
distribution of SHP-1. Site-directed mutagenesis revealed that
a short KRK sequence at the extreme end of the C-terminal
domain was necessary and sufficient for SHP-1 nuclear import.
Mutation of this basic domain prevented the entry of SHP-1
into the nuclear compartment, resulting in the accumulation of
SHP-1 in the cytoplasm. Generally, NLSs are either contigu-
ous, as in the case of SV40 large T antigen, or bipartite, as
illustrated by nucleoplasmin. In a bipartite NLS, neither basic
FIG. 6. The basic domains of SHP-1.
A, comparison of the C-terminal segments
of SHP-1 and SHP-2, showing the three
basic domains (BD1– BD3) of SHP-1. B,
comparison of BD1 with the NLS of SV40
large T-antigen and interferon g (IFN-g).
C, BD2 and BD3 together resemble the
bipartite NLS of nucleoplasmin and other
proteins, including pRb, c-Jun, and p53.
Also shown is the bipartite NLS of the
protein-tyrosine phosphatase TC-PTP.
FIG. 7. Mutation analysis of the C-
terminal domain of SHP-1. The fluo-
rescence localization of GFP-tagged
SHP-1 containing mutations of the three
basic domains within the C-terminal do-
main is shown. Overexpressed SHP-1
lacking BD1 or BD2 remains nuclear (A
and B), whereas mutation of BD3 pre-
vents nuclear import (C). The SHP-1 pro-
tein containing mutations in both BD2
and BD3 is also excluded from the nu-
cleus (D).
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region can function independently to target proteins to the
nucleus. In SHP-1, BD2 (KVKK) and BD3 (KRK) together
resemble a bipartite NLS. However, mutation of BD3 appears
to completely prevent nuclear import and implies that BD3 acts
independently of BD2. Furthermore, mutation of BD2 imparts
no observable change to the intracellular distribution of SHP-1.
Therefore, the BD2 and BD3 motifs of SHP-1, although resem-
bling a bipartite NLS, do not appear to function in this way.
However, it would be extraordinary for a KRK sequence to
direct nuclear import alone. It might be that BD2 and BD3 do
function synergistically to direct the nuclear import of SHP-1,
with BD3 being the more potent half of the partnership. This is
not unprecedented; T-cell PTP (TC-PTP) is another example of
a PTP that possesses a functional NLS (Fig. 6C), the bipartite
nature of which remains controversial. In one investigation,
the upstream region of the T-cell PTP NLS appears not to
function in nuclear import (27). Yet in a later and more detailed
study, both basic regions of the T-cell PTP NLS were shown to
be required for efficient nuclear import but with each basic
region functioning independently to a limited degree (28).
Therefore, it remains undetermined whether the NLS of SHP-1
is truly bipartite, with further investigation necessary.
The biological importance of SHP-1 nuclear import is not
defined. The clear difference in SHP-1 distribution between
hemopoietic and nonhemopoietic cells implies that the traffick-
ing of SHP-1 is under tight regulation in each cell type. In
hemopoietic cells, SHP-1 must be exported from the nucleus or
the C-terminal NLS must be silenced for SHP-1 to remain in
the cytoplasm. This could be brought about by phosphorylation
of amino acid residues within close proximity to the NLS or by
masking of the NLS by protein-protein interaction. On the
other hand, alternative splicing of SHP-1 may remove the
region of the gene encoding the NLS. TC-PTP exists as two
isoforms generated by differential splicing, one isoform di-
rected to the nucleus and the other directed to the endoplasmic
reticulum because of the addition of a stretch of hydrophobic
residues (27). Several other PTPs exist in two forms targeted to
distinct intracellular locations, including PTPf/GLEPP-1 (29)
and DPTP61F (30). Interestingly, differential splicing of the
SHP-1 gene has recently been reported, which produces the 70
kDa protein SHP-1L, which differs from SHP-1 in its C-termi-
nal structure (31). The SHP-1L splice variant does not possess
the BD3 domain shown to direct nuclear import. This raises the
question of whether differential splicing of the SHP-1 gene
could regulate SHP-1 localization, which in turn could regulate
SHP-1 function by directing SHP-1 to target substrates at
distinct cellular localities. However, the anti-SHP-1 antibody
used in these studies was raised to the C-terminal domain of
the protein and will only detect SHP-1 (not SHP-1L); thus the
differential localization of endogenous SHP-1 proteins in hemo-
poietic and nonhemopoietic cells is more likely to be due to
silencing of the NLS or enhanced nuclear export.
The import of SHP-1 into the nucleus of nonhemopoietic cells
may serve as a mechanism by which SHP-1 function is regu-
lated. SHP-1 might be localized within the nucleus to prevent
interaction with cytoplasmic signaling molecules or might be
directed toward unknown nuclear phosphoproteins. It has been
reported that SHP-1 can act as a positive regulator of cell
signaling in nonhemopoietic HEK293 and HeLa cells. It was
speculated that this might be due to the selective dephospho-
rylation of tyrosine residues that have inhibitory signaling
roles. Here we show that in these cell types, SHP-1 is present
within the nucleus. Furthermore, we have demonstrated that
SHP-1 is strikingly excluded from the nucleus of three hemo-
poietic cell lines, the first time that SHP-1 localization has been
shown to be different within contrasting cell types. Conse-
quently, it might be that SHP-1 performs its positive role by
dephosphorylating nuclear tyrosine-phosphorylated proteins.
Because SHP-1 is overexpressed in a variety of malignant
nonhemopoietic cells, identifying targets of nuclear SHP-1 de-
phosphorylation is critical in understanding the role of SHP-1
in tumorigenesis. Relatively few nuclear tyrosine-phosphoryl-
ated proteins have been identified. However, potential targets
for nuclear PTPs are the STAT proteins, which are activated by
tyrosine phosphorylation and translocate to the nucleus (32).
The tyrosine dephosphorylation event that switches off acti-
vated STAT-1 has been localized to the nucleus, but as yet the
PTP(s) involved have not been identified (33, 34). This would
provide a role for SHP-1 in directly regulating gene expression.
Studies to identify novel nuclear targets of SHP-1 are under
way.
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